Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer |
| |
| Authors: | Efthymia D. Tsakiridou Evangelos Liberopoulos Zoe Giotaki Stelios Tigas |
| |
| Affiliation: | 1. Department of Endocrinology, Ioannina University Hospital, Ioannina, Greece;2. Department of Internal Medicine, Ioannina University Hospital, Ioannina, Greece |
| |
| Abstract: | We report the case of a patient with probable heterozygous familial hypercholesterolemia and mitotane-induced resistant hypercholesterolemia, despite combination therapy with rosuvastatin and ezetimibe. The patient was managed with the addition of evolocumab. Use of a proprotein convertase subtilisin-kexin type 9 inhibitor, should be considered in patients who develop mitotane-related hypercholesterolemia that cannot be managed with conventional lipid-lowering treatment. |
| |
| Keywords: | Mitotane Adrenocortical carcinoma ACC Hypercholesterolemia PCSK9 inhibitors PCSK9 Evolocumab |
| 本文献已被 ScienceDirect 等数据库收录！ |
